FDA Suspends U.S. License of Chikungunya Vaccine

Follow Drugslib on

By Stephanie Brown HealthDay Reporter

Medically reviewed by Drugs.com

via HealthDay

MONDAY, Aug. 25, 2025 -- The U.S. Food and Drug Administration is suspending the biologics license for the live-attenuated chikungunya vaccine, Ixchiq, in the United States. The move comes after reports of serious side effects in older adults similar to the symptoms of chikungunya virus.

Chikungunya virus is a mosquito-borne disease causing fever, rash, headache, nausea, fatigue, and severe joint and muscle pain, which can be long-lasting and debilitating.

The FDA granted accelerated approval of Ixchiq in November 2023 to prevent chikungunya virus in adults 18 years and older with an increased risk for exposure.

However, according to the FDA Vaccine Adverse Event Reporting System, Ixchiq has been linked to one confirmed encephalitis death, more than 20 serious adverse events resembling chikungunya illness, 21 hospitalizations, and three deaths in total. In addition, the FDA Center for Biologics Evaluation and Research has determined the vaccine's clinical benefit remains unproven, its risks outweigh potential benefits in most scenarios, and continued use would endanger public health.

Valneva, the manufacturer of Ixchiq, maintains the reported cases align with known trial and postmarketing data, especially in older adults already flagged in prescribing warnings. The company is investigating further and may take additional action regarding the FDA decision.

"As we determine potential next steps, and as the clear threat of chikungunya continues to escalate globally, Valneva remains fully committed to maintaining access to our vaccine as a global health tool for addressing and preventing outbreaks of this devastating illness," Thomas Lingelbach, the chief executive officer of Valneva, said in a statement. "We aim to continue providing Ixchiq to all countries where the product is licensed and continue our efforts with our partners to accelerate vaccine access in low-and-middle-income chikungunya-endemic countries."

Meanwhile, Valneva will immediately stop shipping and selling the vaccine in the United States.

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-08-26 12:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords